Literature DB >> 12911253

Central serous chorioretinopathy in African Americans.

Uday R Desai1, Amir A Alhalel, Thomas J Campen, Rhett M Schiffman, Paul A Edwards, Gordon R Jacobsen.   

Abstract

PURPOSE: Central Serous Chorioretinopathy (CSCR) is presumed to be less prevalent in the African American population. The purpose of this study was to compare the characteristics of CSCR in African Americans and Caucasians.
METHODS: A retrospective analysis was performed. Visual acuity (VA) evaluations that were recorded included best-corrected VA at diagnosis, worst VA recorded at follow-up, and best-corrected VA at the last clinic visit. Recurrences of CSCR, frequency of laser photocoagulation, and fluorescein angiographic patterns also were evaluated.
RESULTS: Of the 74 patients with CSCR, 15 (20.3%) were African American and 59 (79.7%) were Caucasian. This ethnic distribution was similar to the ethnic distribution in the entire Henry Ford Health System population. The mean VA at presentation was significantly lower in African-Americans (20/55 vs. 20/30, P=0.004) and trended towards being lower during follow-up (20/58 vs. 20/32, P=0.04) and at final examination (20/28 vs. 20/22, P=0.04). Mean length of follow-up was 21 months for both groups.
CONCLUSION: The rates and spectrum of symptomatic CSCR seen at Henry Ford Health System are comparable in African Americans and Caucasians.

Entities:  

Mesh:

Year:  2003        PMID: 12911253      PMCID: PMC2594640     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  19 in total

1.  Number, shape, and topography of leakage points in acute type I central serous retinopathy.

Authors:  M Spitznas; J Huke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

2.  Central serous retinopathy: a preliminary report of 33 cases.

Authors:  V O Eu-sen
Journal:  Med J Malaya       Date:  1969-09

3.  Photocoagulation in central serous retinopathy.

Authors:  B Patnaik; R Kalsi; S R Malik
Journal:  Indian J Ophthalmol       Date:  1974-06       Impact factor: 1.848

4.  New visual acuity charts for clinical research.

Authors:  F L Ferris; A Kassoff; G H Bresnick; I Bailey
Journal:  Am J Ophthalmol       Date:  1982-07       Impact factor: 5.258

5.  Subretinal fibrosis and nonrhegmatogenous retinal detachment associated with multifocal central serous chorioretinopathy.

Authors:  T Sharma; S S Badrinath; L Gopal; K Ravishankar; M P Shanmugam; P Bhende; M Bhende; N S Shetty; D A Deshpande; B N Mukesh
Journal:  Retina       Date:  1998       Impact factor: 4.256

6.  Argon laser photocoagulation in the treatment of central serous retinopathy.

Authors:  P Leaver; C Williams
Journal:  Br J Ophthalmol       Date:  1979-10       Impact factor: 4.638

Review 7.  Type-A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Retina       Date:  1987       Impact factor: 4.256

8.  Idiopathic central serous retinopathy in China: a report of 600 cases (624 eyes) treated by acupuncture.

Authors:  J G Lu; T R Friberg
Journal:  Ophthalmic Surg       Date:  1987-08

9.  Central serous retinopathy: variants.

Authors:  D E Mazzuca; W E Benson
Journal:  Surv Ophthalmol       Date:  1986 Nov-Dec       Impact factor: 6.048

10.  Central serous retinopathy in leprosy.

Authors:  P A Lamba; R Srinivasan
Journal:  Lepr India       Date:  1983-04
View more
  17 in total

Review 1.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

2.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

3.  Central serous chorioretinopathy: from glucocorticoids to light intensity.

Authors:  Amir Norouzpour; Majid Abrishami
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

Review 4.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

5.  Angiographic characteristics of central serous chorioretinopathy in an Egyptian population.

Authors:  Maha M Shahin
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

6.  Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up.

Authors:  John M Katsimpris; Constantin J Pournaras; Carlos W Sehgelmeble; Ioannis K Petropoulos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-12       Impact factor: 3.117

7.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

Review 8.  [Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on central serous chorioretinopathy : Status 18 October 2021].

Authors: 
Journal:  Ophthalmologe       Date:  2021-12-14       Impact factor: 1.059

9.  Quality of life of patients with central serous chorioretinopathy - a major cause of vision threat among middle-aged individuals.

Authors:  Izabella Karska-Basta; Weronika Pociej-Marciak; Michał Chrząszcz; Katarzyna Żuber-Łaskawiec; Marek Sanak; Bożena Romanowska-Dixon
Journal:  Arch Med Sci       Date:  2020-01-29       Impact factor: 3.318

10.  Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study.

Authors:  Der-Chong Tsai; Shih-Jen Chen; Chin-Chou Huang; Pesus Chou; Chia-Min Chung; Po-Hsun Huang; Shing-Jong Lin; Jaw-Wen Chen; Tseng-Ji Chen; Hsin-Bang Leu; Wan-Leong Chan
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.